LLY — All updates

Okay , now I'm going to move on to a completely different sector, which is the healthcare sector . I will talk about Eli Lilly. Again, this may not have been a name that many investors were following, unless you were following the healthcare and pharmaceutical sectors until the last couple of years, with the GLP-1 boom.

Eli Liy could be a $2,000 stock in the next three to four years. That is coming from Home Depot co-founder Ken Langon.

Home Depot, ticker HD, their co-founder Ken Langon, stated that the Mangaro maker Eli Liy, ticker LLY, could reach $2,000 per share within the next three to four years, noting that the drug maker is currently challenging Home Depot as its largest personal investment holding.

Speaking on CNBC's Squawkbox, the uh Invimed Associates chairman and president said, "Eli Lily is giving Home Depot a real run for the top spot in his portfolio." Quote, "I think Lily is going to be a $2,000 stock in the next three to four years."

End quote. Langode said that during the broadcast, and this target is 70.92% higher than Tuesday's closing price. Quote, "Home Depot better get off its rear because Lily may become the number one in this old guy's portfolio." End quote.

And I think while Novo has a good oral wgoi drug that is launching well to be fair and is still one of their bright spots uh the question is in five years is Lily's foundo going to be at or above but most importantly as we've talked about the injectable market is still going to be 65 or 75% of the overall market and Lily's got not only tepatide but you're going to hear about in a month or two the triple G which I think a lot of people including in Silicon Valley are compounding a bit the triple G and also amalin which you're going to hear about which has very high efficacy and not a lot of side effect.

to take a look at the performance of Eli Lilly's stock over the past year. This stock has largely, and in many ways, become the benchmark for the pharmaceutical industry. Stocks rose by about 50% during this period, but have fallen by more than 10% since reaching their all-time high about a month ago.

looking at Eli Lilly today, which got an upgrade, Diane. It did. It did. So, Berenberg moving off the sidelines on Eli Lilly. They're injecting it with an upgrade here, up to a buy from a hold.

They've set a new price target of 1,400. That's up from 1,220. That signals more than 20% upside.

Now, kicking things off here with the relatively safer pick first, we have the juggernaut biotech, Eli Liy, ticker symbol LLY, who's been making enormous strides in what we call peptidebased medicines.

C peptides are short chains of amino acid that are inherently modular, meaning that they're almost like biological building blocks that AI can more effectively design and modify with extreme precision.

It's almost like editing lines of computer code for it.